Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Burns pipeline constitutes 12+ key companies continuously working towards developing 12+ Burns treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Burns Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Burns Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Burns Market.

Some of the key takeaways from the Burns Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Burns treatment therapies with a considerable amount of success over the years.

*
Burns companies working in the treatment market are NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others, are developing therapies for the Burns treatment

*
Emerging Burns therapies in the different phases of clinical trials are- NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkin Trademark , and others are expected to have a significant impact on the Burns market in the coming years.

*
In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, announced today that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid Registered (anacaulase-bcdb), enabling eschar removal in pediatric patients from newborn to eighteen years old with deep partial- and/or full-thickness thermal burns. With this FDA approval, NexoBrid is now authorized for use in the U.S. across all age groups, in line with its approvals in the European Union and Japan.

*
In November 2023, Aegle Therapeutics Corp., a biotechnology company in the clinical stage, focusing on innovative extracellular vesicle ("EV") therapies for rare and serious diseases, has announced the commencement of dosing for the first patient in the Phase 1/2a clinical trial of AGLE-102 Trademark . This trial aims to evaluate AGLE-102 Trademark for the treatment of severe second-degree burns. AGLE-102 Trademark is an investigational product composed of native extracellular vesicles derived from allogeneic stem cells, utilizing Aegle's proprietary and patented techniques. These vesicles are a combination of cell-derived nanoparticles containing active biomolecules, including proteins and nucleic acids, known for their tissue regeneration, immunomodulation, and anti-inflammatory properties.

Burns Overview

Burns are injuries to the skin or other tissues caused by heat, radiation, electricity, chemicals, or friction. They vary in severity from minor to life-threatening and can result in damage to the skin, underlying tissues, and even organs. Burns are classified based on their depth and extent, commonly categorized as first-degree, second-degree, third-degree, and fourth-degree burns.

Get a Free Sample PDF Report to know more about Burns Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/burns-pipeline-insight [https://www.delveinsight.com/report-store/burns-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Burns Drugs Under Different Phases of Clinical Development Include:

*
NMT-cNP8: NeoMatrix Therapeutics, Inc.

*
TOP-N44: Topadur

*
PXS-6302: Pharmaxis Ltd

*
NMT- cP12: NeoMatrix Therapeutics, Inc

*
MW-III: Skingenix, Inc

*
DenovoSkin Trademark : CUTISS AG

Burns Route of Administration

Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

*
Molecule Type

Burns Molecule Type

Burns Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Burns Pipeline Therapeutics Assessment

*
Burns Assessment by Product Type

*
Burns By Stage and Product Type

*
Burns Assessment by Route of Administration

*
Burns By Stage and Route of Administration

*
Burns Assessment by Molecule Type

*
Burns by Stage and Molecule Type

DelveInsight's Burns Report covers around products under different phases of clinical development like development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Burns product details are provided in the report. Download the Burns pipeline report to learn more about the emerging Burns therapies [https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Burns Therapeutics Market include:

Key companies developing therapies for Burns are - Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.

Burns Pipeline Analysis:

The Burns pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Burns with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Burns Treatment.

*
Burns key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Burns Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Burns market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Burns drugs and therapies [https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Burns Pipeline Market Drivers

*
Rising incidence of burns, high demand of Skin grafts, growing awareness of available treatment options are some of the important factors that are fueling the Burns Market.

Burns Pipeline Market Barriers

*
However, stringent regulatory approval, high cost of treatment and other factors are creating obstacles in the Burns Market growth.

Scope of Burns Pipeline Drug Insight

*
Coverage: Global

*
Key Burns Companies: NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others

*
Key Burns Therapies: NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkin Trademark , and others

*
Burns Therapeutic Assessment: Burns current marketed and Burns emerging therapies

*
Burns Market Dynamics: Burns market drivers and Burns market barriers

Request for Sample PDF Report for Burns Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Burns Report Introduction

2. Burns Executive Summary

3. Burns Overview

4. Burns- Analytical Perspective In-depth Commercial Assessment

5. Burns Pipeline Therapeutics

6. Burns Late Stage Products (Phase II/III)

7. Burns Mid Stage Products (Phase II)

8. Burns Early Stage Products (Phase I)

9. Burns Preclinical Stage Products

10. Burns Therapeutics Assessment

11. Burns Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Burns Key Companies

14. Burns Key Products

15. Burns Unmet Needs

16 . Burns Market Drivers and Barriers

17. Burns Future Perspectives and Conclusion

18. Burns Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=burns-pipeline-2024-indepth-clinical-trials-analysis-and-emerging-therapies-report-by-delveinsight-mediwound-kaken-pharma-kerecis-medline-mallinckrodt-pharma-avita-medical-vericel-corp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.